After an FDA panel unanimously voted in favor of approving GW Pharmaceuticals' (GWPH) Epidiolex, Mizuho analyst Difei Yang reiterates a Buy rating on Zogenix (ZGNX) with a $51 price target. Superior efficacy of Zogenix competitor ZX008, as demonstrated in the most recent Phase 3 results, means that FDA approval would be highly likely assuming positive data from the second Phase 3 study, expected in June, Yang tells investors in a research note. She believes readouts on the study could be an important share moving event and are "highly likely" to be positive.